SCHEMBL6360902

SCHEMBL6360902

O=C(Nc1cccc(Cl)c1Cl)C(OCc1ccccc1)c1cccc(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPIA P62937 1/20 0.47
MEN1 O00255 6/20 0.46
KMT2A Q03164 6/20 0.46
MAPT P10636 4/20 0.46
LMNA P02545 3/20 0.46
ALDH1A1 P00352 5/20 0.44
KDM4E B2RXH2 1/20 0.43
KCNQ2 O43526 2/20 0.43
HTT P42858 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
HDAC7 Q8WUI4 1/20 0.42
ACP1 P24666 1/20 0.42
PTPN12 Q05209 1/20 0.42
PTPN13 Q12923 1/20 0.42
SSU72 Q9NP77 1/20 0.42
NPSR1 Q6W5P4 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
NPC1 O15118 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9077243 0.80 MEN1 (0.49) MEN1KMT2ALMNA
SCHEMBL10445132 0.71 MEN1 (0.59) MEN1KMT2AMAPTLMNAALDH1A1
SCHEMBL17833423 0.70 ALDH1A1 (0.57) PPIAMEN1KMT2AMAPTLMNA
SCHEMBL10339126 0.70 LMNA (0.61) MEN1KMT2AMAPTLMNAALDH1A1
SCHEMBL10334664 0.69 SLC1A3 (0.46) MEN1KMT2AALDH1A1NPC1RAB9A
SCHEMBL6360899 0.69 PTGER1 (0.54) PPIAMEN1KMT2AMAPTALDH1A1
SCHEMBL20346324 0.68 HCAR2 (0.50) MEN1KMT2AMAPTLMNAALDH1A1
SCHEMBL29291234 0.68 CTSD (0.51) MEN1KMT2AMAPTALDH1A1HTT
SCHEMBL11017480 0.67 KLK7 (0.52) PPIAMEN1KMT2AMAPTLMNA
SCHEMBL11911572 0.67 NPC1 (0.50) MEN1KMT2ALMNAALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US claimed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP claimed
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US disclosed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists TFAM, CYP11B2, CYP11B1 PPIA 1834/4885MEN1 3860/4885KMT2A 1711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.